Advancing Breast Cancer Screening With A Non-invasive Blood Test
About BCAL Diagnostics
BCAL Diagnostics (ASX: BDX) is an Australian and US-based biotechnology company dedicated to advancing early and accurate breast cancer detection.
Our innovative, non-invasive blood test is designed to complement existing screening methods, empowering women and their clinicians with greater confidence in diagnostic outcomes. By improving screening accuracy and reducing unnecessary follow-ups, we aim to enable timely intervention and better health outcomes for women worldwide.
The Board of BCAL Diagnostics is committed to transparency, integrity, and accountability, ensuring our governance framework supports long-term growth and sustainability.
A strong, values-based governance structure is fundamental to our company, guiding ethical decision-making and responsible business practices. We align with best practice principles and the ASX Corporate Governance Council’s recommendations to uphold these standards.
For more details, download our key policies below.
